Drug Trial Radar · NCT03687255
Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections
Last checked: Nov 19, 2026Latest source record: Mar 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,043
Actual
Start
Sep 24, 2018
Primary completion
Jan 30, 2020
Study completion Feb 15, 2020
Sponsor
- Lead sponsor
- AllecraIndustry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Sep 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-center, randomized, double-blind, non-inferiority study of cefepime 2 g/AAI101 500 mg combination compared to piperacillin 4 g/tazobactam 500 mg in a population of adult patients with cUTI or AP. The study will be conducted in approximately 115 sites located in the EU, the US, Central, South America and South Africa.
Conditions
- Urinary Tract Infections
Interventions
cefepime/AAI101 combinationDrug
cefepime 2 g / AAI101 500 mg
Piperacillin/tazobactamDrug
piperacillin 4 GM / tazobactam 500 MG
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients in the Microbiological Modified Intent to Treat (m-MITT) Population who achieve overall treatment success at Test Of Cure (TOC)Time frame: 7 days after EOT [±2 days] for patients receiving 7 days of treatment and 19 days after randomization [±2 days] for patients receiving more than 7 days of treatment.
Locations
24 sites in 19 countries. Site status is shown where the registry gives one.
St. Josephs Clinical Research
Anaheim, California
Southbay Pharma Research
Buena Park, California
Florida Urology Partners
Tampa, Florida
Washington University School of Medicine
St Louis, Missouri
Mercury Street Medical
Butte, Montana
University of New Mexico Health Sciences Center
Albuquerque, New Mexico
HIGA Dr Ramon Carrillo
Buenos Aires, Argentina
Brest Regional Hospital
Brest, Belarus
MHAT Rahila Angelova AD, Pernik
Pernik, Bulgaria
University Hospital for Infectious Diseases "Dr. Fran Mihaljevic" Department for general infectious diseases
Zagreb, Croatia
Tartu University Hospital
Tartu, Estonia
Unimed Adjara - Kutaisi oncological centre
Kutaisi, Georgia
Bugat Pal Korhaz
Gyöngyös, Hungary
Uroklinika, LLC
Riga, Latvia
Republican Siauliai caunty hospital
Šiauliai, Lithuania
Centro Especializado en Investigación Clínica S.C.
Boca del Río, Mexico
Clinica Internacional - Sede San Borja
Lima, Peru
Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Klinika Chorob Wewnetrznych, Nefrologii i Transplantologii
Warsaw, Poland
Scientific Research Center Eco-Safety
Saint Petersburg, Russia
Clinical Hospital Center Zvezdara
Belgrade, Serbia
Interne oddelenie, Nemocnica Malacky, Nemocnicna a.s.
Malacky, Slovakia
Clinical Projects Research
Worcester, South Africa
Hospital del Mar, Department of Infectious Disease
Barcelona, Spain
Chernihiv City Hospital #2 of Chernihiv City Council, department of Urology
Chernihiv, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.